# Interferon and Ribavirin Treatment in Patients With Hemoglobinopathies

> **NCT00887081** · PHASE4 · UNKNOWN · sponsor: **Azienda Ospedaliera V. Cervello** · enrollment: 150 (estimated)

## Conditions studied

- Hemoglobinopathies

## Interventions

- **DRUG:** PEG-IFN alpha2a or PEG-IFN alpha2b and Ribavirin

## Key facts

- **NCT ID:** NCT00887081
- **Lead sponsor:** Azienda Ospedaliera V. Cervello
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2009-01
- **Primary completion:** 2013-12
- **Final completion:** 2013-12
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2009-04-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00887081

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00887081, "Interferon and Ribavirin Treatment in Patients With Hemoglobinopathies". Retrieved via MORVS 2026-11-03 from https://api.morvs.ai/clinical/NCT00887081. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*